Abstract Chronic inflammation significantly contributes to the pathogenesis of several neurodegenerative disorders. In physiological conditions, a chronic inflammatory state is prevented through the termination of the acute inflammatory response once the triggering insult is eliminated. Several mechanisms regulate the resolution of inflammation. Among these, a potent inhibitor of the pro-inflammatory NF-kB signaling known as A20 has emerged as a key player. Recent studies have shown reduced blood levels of A20 in the patients of diverse chronic inflammatory diseases. Similar results have also been demonstrated in patients of multiple sclerosis (MS), a neurodegenerative disease characterized by persisting inflammation. In the present study, we investigate whether other similar neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS) also demonstrate deregulated levels of A20 expression as compared to healthy controls (HC) and treatment-naive MS patients. Our results confirm previous data that the A20 expression is reduced in whole blood of MS patients as compared to HC. Additionally, we demonstrate that significantly diminished A20 expression is also evident in PD patients. The dysregulation of the A20 pathway could then contribute to the persistence of inflammation in these disorders. It would thus be interesting to investigate further whether such commonly deregulated pathways between different inflammatory diseases could represent novel targets for therapy.
Introduction
Inflammation in physiological conditions is a beneficial host response to external challenge or cellular injury. It leads to the activation of a complex array of inflammatory mediators that establish both an innate and acquired immune response (Serhan and Savill 2005) . This is an essential protective mechanism for the restoration of tissue structure and function to maintain homeostasis (Perry et al. 2007) . It is a strictly controlled and self-limiting process wherein the complex interplay and balance of the pro-inflammatory and the antiinflammatory molecules are vitally important. Prolonged or non-resolving inflammatory events can evolve into a detrimental process that can lead to chronic inflammatory disorders including autoimmune and neurodegenerative diseases (Perry et al. 2007 ). Under physiological conditions, inflammation involves the sequential activation of multiple signaling pathways out of which some are of particular interest given Serena Martire and Francesca Montarolo contributed equally to this work. their possible therapeutic implications. Especially, cellular pathways involving the pro-inflammatory nuclear factor kB (NF-kB) have been extensively studied in this context (Lawrence et al. 2001) . NF-kB induces inflammatory responses by activating the transcription of pro-inflammatory mediators and response genes which lead to the recruitment and activation of various immune cells (Ruland 2011) . However, once the stimuli has been eliminated, NF-kB signaling needs to be tightly down-regulated for the resolution of inflammation and prevention of disease (Ruland 2011) . The non-resolution of inflammation due to deregulation of NF-kB signaling has been linked to the pathogenesis of multiple neurodegenerative disorders (Lanzillotta et al. 2015; Tokunaga 2013) , including multiple sclerosis (MS) (Mc Guire et al. 2013 ), Parkinson's disease (PD) (Baiguera et al. 2012; Pranski et al. 2013 ), Alzheimer's disease (AD) (Ascolani et al. 2012) , and amyotrophic lateral sclerosis (ALS) (Frakes et al. 2014; Prell et al. 2014) . Multiple mechanisms usually ensure the proper termination of NF-kB action. Among these, A20 enzyme has now emerged as the most potent inhibitor of NF-kB by restricting the duration and intensity of its action (Ruland 2011) . Thus, it might be of particular interest to investigate the role of A20 in other chronic inflammatory diseases and further explore its therapeutic potential. A20 is a ubiquitin-editing enzyme encoded by the TNFAIP3 gene. It belongs to the ubiquitin proteasome which is the primary quality control system of cellular proteins. It negatively regulates NF-kB signaling by the ubiquitination of different NF-kB signaling molecules (Shembade et al. 2010 ) that are then degraded by the proteasome. Therefore, A20 has emerged as a central gatekeeper of inflammation and immunity in both mice and humans (Lee et al. 2000; Majumdar and Paul 2014) . A20-deficient mice develop cachexia and severe multiorgan inflammation resulting in premature lethality (Lee et al. 2000) . In humans, polymorphisms within the TNFAIP3 locus have been associated with several autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis (Mele et al. 2014) , and recently multiple sclerosis (MS) (IMSGC et al. 2013) . MS is the most prevalent autoimmune disease of the central nervous system (CNS), characterized by chronic inflammation with immune cells infiltration, demyelination, and axonal damage. In our previous studies, we have observed A20 downregulation in the whole blood and peripheral blood mononuclear cells of MS patients (Gilli et al. 2010 (Gilli et al. , 2011 Navone et al. 2014) . This may suggest a deregulation of anti-inflammatory mechanisms in MS underlying both the pro-inflammatory phenotype and over-activation of the immune system. This hypothesis was confirmed by our subsequent investigations that demonstrate a negative correlation between the A20 gene expression level and the clinical outcome of the disease (Gilli et al. 2010) . Therefore, we reasoned that a deregulated expression of the NF-kB inhibitor A20 may play a key role in the pathogenesis of other inflammatory disorders of the CNS as well. To test this hypothesis, we studied the A20 gene expression in the whole blood of patients of several neurodegenerative diseases, such as AD, PD, and ALS, compared to MS patients and healthy controls (HC).
Materials and Methods

Patients and Controls
The present study has been undertaken as a collaborative effort between three Centers of Neurology in Piedmont, Italy. The total number of patients enrolled were 20 each for AD and PD and 36 for ALS along with 40 HC. The blood samples of 34 treatment-naive relapsing-remitting MS (RRMS) patients diagnosed according to the revised McDonald criteria (Polman et al. 2011) were provided by the Biobank of the Regional Referral Center for Multiple Sclerosis (CReSM), San Luigi University Hospital, Orbassano, Italy. Patients with AD and PD were clinically monitored at the Division of Neurology of the Martini Hospital, Turin, Italy, while ALS patients were followed up at "Rita Levi Montalcini" Department of Neuroscience, ALS Expert Center (CRESLA), "Città della Scienza e della Salute," University Hospital, Turin, Italy. Apart from the RRMS group, most of the patients were under treatment with disease-specific drugs at the time of blood sampling. In particular, patients affected by AD were being treated either with donepezil, rivastigmine or memantine alone or combined together; PD patients were being treated with levodopa or dopamine agonists. ALS patients were being treated with riluzole alone or in combination with symptomatic therapies. Each center provided anonymised medical records of patients. Healthy donors included in the study were screened to exclude any neurological or nonneurological disease. All the patients and HC enrolled in the study were from Caucasian origin. This study was approved by Piedmont and San Luigi University Hospital Ethical Committee (N°80/2011, May 25th, 2011) and was conducted in accordance with the ethical standards laid down in the 1964 Helsinki declaration and its later amendments. Informed written consent was obtained from all individual participants included in the study. The demographic and clinical characteristics of patients and HC are summarized in Table 1 .
Gene Expression Analysis
Whole blood samples were collected into Tempus™ Blood RNA Tubes (Thermo Fisher Scientific, MA USA).
Total RNA from blood samples was automatically extracted using the Maxwell® RSC Station and products (Promega, Fitchburg, WI, USA), following the manufacturer's instructions and was reverse-transcribed at final concentration of 10 ng/μL using random hexamer primers (Thermo Fisher Scientific). Gene expression analysis of A20 was performed by real-time PCR using Applied Biosystems' TaqMan gene expression products (Thermo Fisher Scientific). Transcriptional expression was normalized using glyceraldehyde-3-phosphate dehydrogenase (GA3PDH) as a housekeeping gene. For primers and probes, Applied Biosystems' TaqMan® Assay-OnDemand™ gene expression products were used ( T N FA I P 3 , H s 0 0 2 3 4 7 1 3 _ m 1 ; G A 3 P D H , H s 99999905_m1). Expression levels of the A20 gene were calculated by the normalized comparative cycle threshold (Ct) method (2 −ΔΔCt ), using the Universal Human
Reference RNA (Stratagene, Santa Clara, California) for calibration.
Statistical Analysis
Continuous data are presented as medians and ranges and discrete data are given as counts and percentages. Chi-square tests were performed to compare groups of categorical data. Student's t test or Mann-Whitney U test were used to compare continuous data as appropriate. The correlation between A20 gene expression levels and clinical as well as demographical variables was assessed by Pearson correlations and fitting linear models. In particular, we considered (Table 1 ) (I) sex and age at sampling for all the groups; (II) the age at the disease onset and the presence of a family history of the disease for AD, PD, ALS, and MS groups; (III) the presence of pharmacological treatments at the time of sampling (yes/no) and the type of therapy for AD, PD, and ALS; (IV) the presence of symptoms (such as tremors, rigidity, hypokinesia, dystonia, depression, and cognitive impairment), the unified Parkinson's disease rating scale value (UPDRS part III) and the Hoehn and Yahr scale value (H&Y) at the time of sampling for PD patients; (V) the involvement of upper and/or lower motor neurons for ALS patients. Statistical significance was considered at p value <0.05. All analyses were carried out using R version 3.02.
Results
Clinical and demographical data for each cohort of the patients and HC are summarized in Table 1 . There were no significant differences in gender distribution across the groups (chi-square test, p > 0.05). The median age of AD, PD, and ALS groups was higher as compared to HC (Mann-Whitney U test, p < 0.05). In contrast, the median age of MS group was lower as compared to HC (Mann-Whitney U test, p < 0.05). This is due to the earlier age of onset in MS compared to that of PD, AD, and ALS. However, to exclude possible bias due to aging, a correlation analysis was performed in the HC group, to prove that A20 expression is not dependent on age (Pearson correlation, p = 0.46, r = −0.12, Fig. 1a ). Gene expression analysis of A20 was performed in whole blood obtained from 40 HC, 34 untreated MS patients, 20 PD patients, 20 AD patients, and 36 ALS patients. A significant reduction of the A20 transcript level was observed in MS patients with respect to HC (Mann-Whitney U test, p = 0.0007) (Fig. 1b) , confirming our previous data (Gilli et al. 2010 (Gilli et al. , 2011 . Interestingly, PD patients showed a significant reduced A20 level compared to HC (Mann-Whitney U test, p = 0.0001) and even to MS, with a trend toward significance (Mann-Whitney U test, p = 0.08) (Fig. 1b) . Conversely, no differences in A20 expression were detected between HC and both AD and ALS patients (Mann-Whitney U test, p > 0.05) (Fig. 1b) .
Furthermore, correlation analyses between A20 gene expression and disease-specific clinical variables at the time of sampling were performed for AD, PD, and ALS (see Materials and Methods section), with no significant results. Clinical correlations were not performed for the MS patients since a previous study by our group has demonstrated that A20 levels negatively correlate with the clinical course of the disease (Gilli et al. 2011 ) (defined in terms of disability progression, indicated by the Expanded Disability Status Scale-EDSS-and the Annualized Relapse Rate-ARR-during the follow up).
Discussion and Conclusion
A significant body of evidence has implicated the involvement of systemic inflammation in the pathogenesis of neurodegenerative disorders, not only as a contributor to the progression of disease processes but rather as an etiological agent (Perry et al. 2007 ). In recent years, the involvement of NF-kB pathway in neurodegenerative disorders such as MS, PD, AD, and ALS (Mc Guire et al. 2013; Lanzillotta et al. 2015; Tokunaga 2013; Baiguera et al. 2012; Pranski et al. 2013; Ascolani et al. 2012; Frakes et al. 2014; Prell et al. 2014 ) has generated significant interest considering its potential as a novel target for therapy. In Mann-Whitney U test disclosed that A20 was significantly down-regulated in MS and PD patients compared to HC (p = 0.0007 and p = 0.0001, respectively; ***p < 0,001). No differences in A20 transcript levels were detected between HC and the other two neurodegenerative diseases, AD and ALS (b). Relative expression was calculated by the normalized comparative cycle threshold (Ct) method 2 −ΔΔC particular, molecules and mechanisms that inhibit the NF-kB and mitigate the overall inflammatory response are being extensively studied. One such molecule of interest is the A20 enzyme. It plays a key role in the regulation of inflammation and immunity due to its ability to inhibit the NF-kB signaling by a feedback loop mechanism. It has been widely demonstrated that A20 dysfunction results in excessive systemic inflammation and autoimmunity in both human beings and mouse models (Lee et al. 2000; Majumdar and Paul 2014) . In addition, recent evidence has demonstrated a possible link between A20 pathway dysfunction and neuroinflammation as well (Dalal et al. 2012; Abbasi et al. 2015; Guedes et al. 2014) . Systemic and neuronal inflammations are a hallmark of neurodegenerative diseases such as MS. It has been demonstrated that A20 basal expression is significantly reduced in peripheral whole blood and lymphomonocytes of several independent cohorts of drug-naïve MS patients compare to HC (Gilli et al. 2010 (Gilli et al. , 2011 Navone et al. 2014) . This study for the first time aims to investigate a possible A20 gene expression deregulation in peripheral immune cells of other neurological diseases, such as PD, AD, and ALS in comparison to MS and HC. Here, we confirm our previous data indicating that A20 basal levels are reduced in untreated MS patients compared to HC. In addition, we found a significant A20 down-regulation in PD patients compared to HC and a trend toward significance with respect to MS patients. In contrast, no differences in A20 expression levels were found in AD and ALS patients compared to HC. Furthermore, we found no correlation between gene expression levels and several clinical parameters of any of the diseases under study. This might be due to the small sample size of the stratified cohorts rather than be indicative of an actual lack of association. Additionally, in the current study, with the exception of the treatment-naïve MS group, most patients were receiving treatment at the time of the sample collection. Therefore, the discussion of the possible effects of the ongoing pharmaceutical treatments on the inflammatory processes might be relevant and important. However, this type of investigation was out of the scope of the current study and, to our knowledge, there are no specific studies on the influence of these treatments on A20 expression in the literature as well. Also, very little is known about their potential effects on NF-kB in the immune system. In particular, memantine and riluzole, used for AD and ALS respectively, both aim to block glutamatergic neurotransmission in the CNS through the inactivation of voltagedependent sodium channels on glutamatergic nerve terminals or acting on N-methyl-D-aspartate (NMDA) receptors. Thus, it is plausible that they have no effect on immune system cells, however, no data exists till date on the same. On the contrary, L-dopa and dopamine agonists used for PD, as well as cholinesterase inhibitors (donepezil and rivastigmine) used for AD, may be associated with a reduced NF-kB activity and suppression of the inflammatory response (Takeuchi and Fukunaga 2004; Beck et al. 2004; Tracey 2007; Sun et al. 2013; Pacheco et al. 2009 ). Given such limited data, it is difficult to hypothesize regarding the expected levels of A20 in patients of neurodegenerative disorders undergoing treatment. However, it is known that, in the absence of an underlying dysfunction of the A20 pathway, A20 basal expression is up-regulated by an increase in the activity of NF-kB (Ruland 2011) . Thus, a pharmacological agent that controls the excessive activity of NF-kB, could be in principle expected to maintain the levels of A20 comparable to that of HC. This observation stands true for the AD patients under treatment in this study. However, as mentioned earlier, PD patients continue to show a down-regulation of A20 expression. In our opinion, it is highly unlikely that this downregulation is due to the effect of the drug. Instead, it is highly plausible that this down-regulation is an inherent part of the disease pathology.
The decreased expression of A20 in whole blood from PD patients is an interesting finding in line with the literature as well. The relationship between systemic inflammation and PD has been demonstrated by several studies (Ferrari and Tarelli 2011; Frank-Cannon et al. 2009; Scalzo et al. 2009; Wahner et al. 2007 ). Non-steroidal anti-inflammatory drugs have been successfully used in PD patients to decrease the effects of inflammation and exert a neuroprotective effect (Rees et al. 2011) . Additionally, previous studies have shown that alterations in the ubiquitin proteasome pathway, in which A20 is involved, can contribute to the development and progression of various neurodegenerative disorders, including PD (Wang and Maldonado 2006; Abbasi et al. 2015) . Hence, antiinflammatory mediators such as A20 demand further investigation to determine their potential as promising therapeutic targets. Given that the chief mediator of this pathological inflammation is proven to be the NF-kB pathway (Tokunaga 2013; Baiguera et al. 2012; Pranski et al. 2013; Ferrari and Tarelli 2011) , it is expected that other inhibitors of this pathway maybe dysregulated in these diseases as well. In fact, the reduction of another NF-kB inhibitor, the anti-inflammatory orphan receptor Nurr1, has been observed in peripheral blood cells of both MS (Gilli et al. 2010 (Gilli et al. , 2011 and PD (Le et al. 2008; Montarolo et al. 2016) patients. All of the above factors could collectively influence the disease progression. However, the quest is for a common mechanism that could be shared between diverse neurodegenerative pathologies. The present study could be viewed as one of the first stepping stones wherein we successfully demonstrate at least one pathway that could be similarly dysregulated between two different pathologies, namely PD and MS. We emphasize that further studies are required to clarify the effect of these molecules at the level of cellular sub-populations in both MS and PD.
In conclusion, the present manuscript, although not comprehensive, is meant to provoke further introspection and investigation into whether the pathological levels of inflammation in both MS and PD may involve the breakdown of similar antiinflammatory mechanisms. If indeed true, this may open up doors to novel and perhaps more effective therapeutic targets.
